Home Featured Page 297

Featured

Latest

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Is ‘One...

Former Vancouver Firefighter Declares Psychedelic Drug Saved His Life

Somerville, Massachusetts, Passes Measure to Decriminalize Psychedelics

You Don’t Have to Take Psychedelics to Benefit from Them —...

PTSF 44 (with Colin Thompson, director of “Light Years”)

PT228 – Deborah Snyder from Synergetic Press

PT227- Dr. Anne Wagner – Couples Therapy, MDMA, and MAPS

PT226 – Veronika Gold & Harvey Schwartz from Polaris Insight Center

1...296297298...304 Page 297 of 304

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Is ‘One...

Former Vancouver Firefighter Declares Psychedelic Drug Saved His Life

Somerville, Massachusetts, Passes Measure to Decriminalize Psychedelics

You Don’t Have to Take Psychedelics to Benefit from Them —...

PTSF 44 (with Colin Thompson, director of “Light Years”)

PT228 – Deborah Snyder from Synergetic Press

PTSF 43

PT227- Dr. Anne Wagner – Couples Therapy, MDMA, and MAPS

PTSF 42

PT226 – Veronika Gold & Harvey Schwartz from Polaris Insight Center

EDITOR PICKS

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY